Inhaled \( \beta_2 \) agonists are the mainstay of symptomatic asthma treatment. The introduction of long-acting \( \beta_2 \) agonists has brought a new dimension to symptomatic treatment. The long-lasting bronchodilating effect of this new class of medications is especially desirable for children, who have longer night rests and more frequent periods of extensive physical activity than most adults. Another advantage offered by long-acting \( \beta_2 \) agonists is their twice a day application, which results in increased patient compliance. Formoterol is a new long- and rapid-acting, selective \( \beta_2 \) agonist with a bronchodilator effect lasting 12 hours. In adult patients with asthma, it is currently recommended as an alternative to increasing moderate doses of inhaled corticosteroids or as an adjunct to high doses of inhaled corticosteroids. A survey of the medical literature failed to disclose any studies that have investigated the role of formoterol for the treatment of children with asthma who are symptomatic despite regular use of inhaled corticosteroids.

In a randomised, double blind, placebo controlled, parallel group study we investigated the effect of formoterol treatment in children with bronchial asthma of moderate severity who were symptomatic despite regular use of inhaled corticosteroids.

**Methods**

**PATIENTS**

Thirty two children with asthma (15 boys and 17 girls), ranging in age from 6 to 14 years (mean, 10.25; SEM, 2.31), recruited from the outpatient clinic of the pediatric allergy and asthma division of Hacettepe University School of Medicine were enrolled in the study. All patients met the American Thoracic Society criteria for bronchial asthma and demonstrated at least a 15% change in forced expiratory volume in one second (FEV\(_1\)) within the previous year. Twenty one patients were atopic as determined by skin prick testing. Patients with pollen sensitivity were studied outside the pollen season. All patients had moderate persistent asthma, and were symptomatic despite regular inhaled corticosteroids (400–800 \( \mu \)g/day). Only those patients who had had no asthma exacerbation or respiratory infection within the last month were included in our study. Asthma exacerbation was defined as a sudden increase in asthma symptoms accompanied by signs of dyspnoea that necessitated the addition of systemic corticosteroids or increases in bronchodilator use.

In a survey of the medical literature failed to disclose any studies that have investigated the role of formoterol for the treatment of children with asthma who are symptomatic despite regular use of inhaled corticosteroids.

**Conclusion**

These findings suggest that inhaled formoterol is effective in controlling chronic asthma symptoms in children who are symptomatic despite regular use of inhaled corticosteroids.

(Arch Dis Child 1999;81:45–48)

Keywords: bronchial asthma; formoterol; asthma; randomised controlled trial
Patients were seen at the clinic on three occasions: at the end of the run in period (baseline visit), at the third, and at the sixth week of the treatment period (first and second visits, respectively).

On each visit, lung functions including FEV₁, specific conductance (sGaw), total lung capacity (TLC), and residual volume (RV) were measured. The concentration of methacholine causing a 20% decrease in FEV₁ (PC₂₀) was determined at baseline and second visit only. All measurements were performed at the same time of day (08:00–09:00), starting with sGaw. Inhaled medications were withheld for at least 12 hours before each visit. Throughout our study, the children or their parents were instructed to keep a diary of asthma symptoms. Symptoms of night and daytime cough, wheezing, and shortness of breath were rated on a scale from 0 to 3, giving a maximum possible daily score of 9.

Patients also recorded the best of three measurements of morning and evening peak expiratory flow rates (PEFR) and the number of supplemental β₂ agonist inhalations (salbutamol 100 µg × 2). Compliance with the dosing regimen was assessed by weighing the canisters before and after treatment periods. On each visit blood pressure was measured, and an electrocardiogram (ECG) and blood chemistry measurements (glucose and potassium) were performed on each patient.

### Pulmonary Function Tests
Specific conductance, TLC, and RV were measured in a whole body, pressure/volume (flow) plethysmograph (Autobox DL 6200; Sensor Medics Co, Anaheim, California, USA) and results were given as per cent of predicted. Patients were instructed to pant slowly (<1 Hz) to minimise the overestimation of lung volume, which has been reported to occur in the presence of airway obstruction.¹ Each measurement was repeated until three reproducible results within 10% of each other were obtained with consistent effort; the mean of these three measurements was recorded.

Forced expiratory manoeuvres were recorded on a dry rolling seal spirometer (2130 Spirometer; Sensor Medics Co) and the maximal value of three FEV₁ measurements was selected.

Methacholine challenge was carried out according to a previously described protocol,⁵ which is a modification of Cockroft’s.⁶ Briefly, after saline inhalation, doubling concentrations of methacholine solution were inhaled during a two minute tidal breathing period every five minutes, starting with 0.03 mg/ml until a fall in FEV₁ of at least 20% was obtained. PC₂₀ was calculated by linear interpolation on the log dose response curve. The aerosols were generated by a nebuliser (Model 646; DeVilbiss Co, Somerset, Pennsylvania, USA) attached to an air compressor (Pulmo-Aid; DeVilbiss Co) giving an output of 0.23–0.25 ml/minute. The same nebuliser was used for each challenge. Duplicate spirometry was performed at 0.5 and 1.5 minutes after each inhalation. The patients wearing nose clips were challenged while their arterial O₂ saturation was continuously monitored for safety reasons.

### Statistical Analysis
The PC₂₀ values were log transformed for analysis and expressed as geometric mean values. The morning and evening PEFR values were calculated as daily means for each two week period. The asthma score and the number of supplemental β₂ agonist uses were given as weekly means. Analysis within each group was performed by the Friedmann two way ANOVA test, and the Wilcoxon test was used whenever the analysis of variance gave significant results. The formoterol and placebo groups were compared using the Mann-Whitney U test. A p value < 0.05, using the two tailed test, was considered to be significant.

---

**Table 1: Characteristics of the two treatment groups**

<table>
<thead>
<tr>
<th></th>
<th>Formoterol</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Boys/girls</td>
<td>7/9</td>
<td>8/8</td>
</tr>
<tr>
<td>Mean follow up (years) (range)</td>
<td>3.09 (1–7.5)</td>
<td>3.34 (1–7)</td>
</tr>
<tr>
<td>Mean steroid use (years) (range)</td>
<td>1.12 (0.5–2.5)</td>
<td>1.58 (0.5–3.3)</td>
</tr>
<tr>
<td>Atopy</td>
<td>11</td>
<td>10</td>
</tr>
</tbody>
</table>

**Table 2: Clinical parameters and lung functions of the two groups**

<table>
<thead>
<tr>
<th></th>
<th>Formoterol (week 0)</th>
<th>Change at first visit (week 3 from baseline)</th>
<th>Change at second visit (week 6 from baseline)</th>
<th>Placebo (week 0)</th>
<th>Change at first visit (week 3 from baseline)</th>
<th>Change at second visit (week 6 from baseline)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁ (% predicted)</td>
<td>79 (60 to 116)</td>
<td>9.5 (−6 to 30)</td>
<td>3.0 (−23 to 29)</td>
<td>80 (63 to 107)</td>
<td>1.0 (−12 to 19)</td>
<td>1.0 (−12 to 19)</td>
</tr>
<tr>
<td>sGaw (% predicted)</td>
<td>77.5 (30 to 150)</td>
<td>3.5 (−8 to 13)</td>
<td>0 (−42 to 107)</td>
<td>62.5 (29 to 96)</td>
<td>2.0 (−37 to 107)</td>
<td>7.5 (−5.8 to 192)</td>
</tr>
<tr>
<td>TLC (% predicted)</td>
<td>103.5 (90 to 187)</td>
<td>4.5 (−14 to 42)</td>
<td>4.5 (−17 to 53)</td>
<td>109 (90 to 125)</td>
<td>2.5 (−34 to 88)</td>
<td>7.5 (−5.8 to 192)</td>
</tr>
<tr>
<td>RV (% predicted)</td>
<td>159 (85 to 352)</td>
<td>1.5 (−9 to 51)</td>
<td>5.5 (−82 to 259)</td>
<td>133 (73 to 304)</td>
<td>−0.5 (−79 to 385)</td>
<td>7.5 (−5.8 to 192)</td>
</tr>
<tr>
<td>FVC (% predicted)</td>
<td>91 (69 to 137)</td>
<td>2.5 (−35 to 35)</td>
<td>1.5 (−31 to 40)</td>
<td>94 (76 to 121)</td>
<td>4.5 (−16 to 84)</td>
<td>3.0 (−9 to 17)</td>
</tr>
<tr>
<td>FRC (% predicted)</td>
<td>132.5 (94 to 234)</td>
<td>4.5 (−42 to 62)</td>
<td>4.5 (−48 to 150)</td>
<td>132.5 (98 to 200)</td>
<td>4.5 (−32 to 186)</td>
<td>6.5 (−14 to 112)</td>
</tr>
<tr>
<td>PC₂₀ (mg/ml)</td>
<td>0.295 (0.04 to 1.87)</td>
<td>0.050 (0.57 to 0.74)</td>
<td>0.3 (0.08 to 2.24)</td>
<td>0.2 (0.08 to 2.24)</td>
<td>0.02 (0.5 to 0.46)</td>
<td>0.02 (0.5 to 0.46)</td>
</tr>
<tr>
<td>mPEFR (l/min)</td>
<td>239.5 (129 to 295)</td>
<td>11.5 (−2 to 206)</td>
<td>21.0 (2 to 181)</td>
<td>21.0 (2 to 181)</td>
<td>11.5 (−2 to 206)</td>
<td>21.0 (2 to 181)</td>
</tr>
<tr>
<td>cPEFR (l/min)</td>
<td>243.5 (139 to 303)</td>
<td>10.5 (−10 to 166)</td>
<td>10.5 (−9 to 148)</td>
<td>210 (145 to 390)</td>
<td>−1.0 (−46 to 50)</td>
<td>0 (−35 to 49)</td>
</tr>
<tr>
<td>vPEFR (%)</td>
<td>2.75 (0.0 to 12)</td>
<td>−1.125 (−9 to 3.33)</td>
<td>−1.12 (−10 to 2.4)</td>
<td>2.0 (0.0 to 17)</td>
<td>−0.2 (−16 to 2.4)</td>
<td>0 (−9 to 17)</td>
</tr>
<tr>
<td>β₂ agonist use* (per week)</td>
<td>3.0 (2 to 6)</td>
<td>−2* (−4 to −1)</td>
<td>−3* (−6 to −2)</td>
<td>3.0 (2 to 10)</td>
<td>−1.0* (−2 to 1)</td>
<td>0 (−2 to 2)</td>
</tr>
<tr>
<td>Asthma symptom score&lt;</td>
<td>3.0 (2 to 67)</td>
<td>−3* (−5 to −2)</td>
<td>−3* (−7 to −2)</td>
<td>3.0 (2 to 10)</td>
<td>−1.0* (−4 to 0)</td>
<td>0 (−1 to 1)</td>
</tr>
</tbody>
</table>

*p < 0.05 compared with the corresponding baseline value (Wilcoxon test).
†Each use consisted of two puffs of salbutamol (100 µg/puff).
‡Night time cough, daytime cough, wheezing or shortness of breath rated on a scale from 0 to 3 (maximum, 9).

ePEFR, evening peak expiratory flow rate; FEV₁, forced expiratory volume in one second; FRC, functional residual capacity; FVC, forced vital capacity; mPEFR, morning peak expiratory flow rate; PC₂₀, 20% decrease in FEV₁; RV, residual volume; sGaw, specific conductance; TLC, total lung capacity; vPEFR, variability of peak expiratory flow rate.
Formoterol in bronchial asthma

Results

Of the 32 children, 16 were treated with placebo and 16 with formoterol during the treatment period. At the time of randomisation, the two groups had similar characteristics (table 1). There were no asthma exacerbations that required systemic corticosteroids during the study periods. Neither an asthmatic attack nor an infection was noted for at least two weeks preceding each clinic visit.

Compliance with the use of study drugs was greater than 85% for each group. There were no differences between the two groups in this regard. Tolerance to formoterol was good in all patients. There was no evidence of effects as measured by ECG changes, blood pressure, and blood chemistry, and no patient complained of headache.

Table 2 summarises the results. Placebo treatment failed to cause any significant changes in any variables during the six weeks of treatment, except lower symptom scores and β₂ agonist use at first visit compared with baseline (p = 0.04 and 0.05, respectively). However, the figures obtained for these same variables were not significantly different from the baseline at the second visit (p > 0.05 for both) (fig 1A and B). On the other hand, formoterol treatment caused significant decreases in symptom scores and β₂ agonist use at both the first and second visits (fig 1A and B; table 2). Both morning and evening PEFR values (at first and second visits) were significantly higher compared with baseline (fig 2; table 2). As expected, PEFR variability followed a similar trend and was significantly lower at first and second visits compared with baseline (table 2).

Discussion

Formoterol, a new long acting bronchodilator, is suggested as an alternative to increasing the amount of inhaled corticosteroids in asthma patients who are symptomatic despite the regular use of these drugs. This recommendation is based on the results of studies conducted in the adult population. Our study suggested that formoterol is effective in improving clinical symptoms as well as some pulmonary function measures in children, and was not associated with adverse effects, at least during the six week treatment period.

Previous studies in children have shown that formoterol may be useful in exercise induced asthma, and that it may increase PEFR and decrease bronchial hyperreactivity. The improvement seen in morning and evening PEFRs clearly shows the sustained bronchodilating action of formoterol. We think that the accompanying decrease in PEFR variability should also be attributed to this bronchodilating effect rather than to a possible anti-inflammatory effect. The fact that formoterol treatment did not affect PC20 values is also indicative of the lack of an anti-inflammatory effect. This might be a result of the small number of children in our study, but this explanation is unlikely because of the complete absence of an effect in any patient. These results are different from those reported by Becker and Simons, where after 12 µg formoterol, airway responsiveness to methacoline was significantly blunted for as long as 12 hours when compared with the placebo. The reasons for the discrepancy between the two studies are unclear. However, all the patients in our study were on inhaled corticosteroids, compounds known to decrease bronchial hyperreactivity significantly, which might explain why formoterol had no additional beneficial effect on hyperreactivity.

Bronchodilation provided by formoterol was sustained throughout the study as reflected by higher PEFR values and lower symptom scores and β₂ agonist use at the end of six weeks. These findings suggest that six weeks of formoterol treatment did not cause the development of tolerance.

In our patients, asthma was associated with lung hyperinflation as indicated by increased TLC and RV values. Previously, we have shown that inhaled corticosteroids can decrease TLC...
in asthmatic children. However, unlike corticosteroids, formoterol does not seem to influence the lung hyperinflation caused by bronchial asthma.

We think that the use of a long acting β₂ agonist should be considered in children in whom inhaled corticosteroids may have the potential to retard linear growth, especially at higher doses. Our results suggest that adding formoterol to inhaled corticosteroids is an effective treatment option in children who are symptomatic despite regular use of inhaled corticosteroids.